AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
• Oramed Pharmaceuticals reported Q3 net income of $65.0 million. • Total assets increased 42% to $220.5 million YoY. • Completed full repayment from Scilex, receiving $27 million. • Basic EPS at $1.30, diluted EPS at $1.26.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet